Pharmacologic management of overactive bladder: Practical options for the primary care physician

American Journal of Medicine

Volumn 119, Issue 3 SUPPL. 1, 2006, Pages 24-28

  Staskin, David R ^a,c   MacDiarmid, Scott A ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c F 918 ^*  (United States)

Author keywords

Anticholinergics; Overactive bladder; Pharmacologic management; Urinary incontinence

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE;

CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; HEALTH STATUS; HEART DISEASE; HUMAN; HYPERTENSION; INCONTINENCE; OVERACTIVE BLADDER; PHYSICIAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOCIAL ISOLATION; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; XEROSTOMIA;

EID: 32444448625     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.12.013     Document Type: Article

References (22)

1. P. Abrams, L. Cardozo, M. Fall Standardisation Sub-committee of the International Continence Society The standardisation of terminology of lower urinary tract function report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 2002 167 178
2. R.A. Appell The newer antimuscarinic drugs bladder control with less dry mouth Cleve Clin J Med 69 2002 761 769
3. I. Milsom, P. Abrams, L. Cardozo, R.G. Roberts, J. Thuroff, A.J. Wein How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU Int 87 2001 760 766
4. W.F. Stewart, J.B. Van Rooyen, G.W. Cundiff Prevalence and burden of overactive bladder in the United States World J Urol 20 2003 327 336
5. J.M. Holroyd-Leduc, S.E. Straus Management of urinary incontinence in women clinical applications JAMA 291 2004 996 999
6. K.E. Andersson Antimuscarinics for treatment of overactive bladder Lancet Neurol 3 2004 46 53
7. R.A. Appell, P. Sand, R. Dmochowski Overactive Bladder: Judging Effective Control and Treatment Study Group Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder results of the OBJECT study Mayo Clin Proc 76 2001 358 363
8. C. Shaw, R. Tansey, C. Jackson, C. Hyde, R. Allan Barriers to help seeking in people with urinary symptoms Fam Pract 18 2001 48 52
9. T.W. Hu, T.H. Wagner Economic considerations in overactive bladder Am J Manag Care 6 suppl 11 2000 S591 S598
10. T.W. Hu, T.H. Wagner, J.D. Bentkover Estimated economic costs of overactive bladder in the United States Urology 61 2003 1123 1128
11. M.A. Siddiqui, C.M. Perry, L.J. Scott Oxybutynin extended-release a review of its use in the management of overactive bladder Drugs 64 2004 885 912
12. R.U. Anderson, D. Mobley, B. Blank, D. Saltzstein, J. Susset, J.S. Brown OROS Oxybutynin Study Group Once daily controlled versus immediate release oxybutynin chloride for urge incontinence J Urol 161 1999 1809 1812
13. P. Van Kerrebroeck, K. Kreder, U. Jonas, N. Zinner, A. Wein Tolterodine Study Group Tolterodine once-daily superior efficacy and tolerability in the treatment of overactive bladder Urology 57 2001 414 421
14. R.R. Dmochowski, P.K. Sand, N.R. Zinner, M.C. Gittelman, G.W. Davila, S.W. Sanders Transdermal Oxybutynin Study Group Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence Urology 62 2003 237 242
15. A.C. Diokno, R.A. Appell, P.K. Sand OPERA Study Group Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder results of the OPERA trial Mayo Clin Proc 78 2003 687 695
16. D.R. Staskin, S.A. MacDiarmid Using anticholinergics to treat overactive bladder the issue of treatment tolerability Am J Med 119 suppl 3A 2006 9S 15S
17. W. Steers, J. Corcos, J. Foote, G. Kralidis An investigation of dose titration with darifenacin, an M3-selective receptor antagonist BJU Int 95 2005 580 586
18. E. Versi, R. Appell, D. Mobley, W. Patton, D. Saltzstein Ditropan XL Study Group Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence Obstet Gynecol 95 2000 718 721
19. D.M. Gleason, J. Susset, C. White, D.R. Munoz, P.K. Sand Ditropan XL Study Group Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence Urology 54 1999 420 423
20. M. O'Leary, J.R. Erickson, C.P. Smith, C. McDermott, J. Horton, M.B. Chancellor Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury J Spinal Cord Med 26 2003 159 162
21. C.R. Chapple, R. Martinez-Garcia, L. Selvaggi STAR Study Group A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome results of the STAR trial Eur Urol 48 2005 464 470
22. S.A. MacDiarmid Overactive bladder improving the efficacy of anticholinergics by dose escalation Curr Urol Rep 4 2003 446 451